CURE is pleased to announce that John G. Houston, Ph.D., has joined CURE’s Board of Directors.
John leads the Disease Sciences and Biologics organization at Bristol-Myers Squibb with responsibility for over 800 employees and an annual budget of over $100MM. He is a member of the BMS R&D Executive Committee reporting to the Head of Discovery and chairs the Target Portfolio Committee which has governance accountability in the early research and development phase.
John has over 26 years of experience in the pharmaceutical industry. With his teams and his research colleagues, he has progressed over 180 compounds into development, several of which have advanced into late stage clinical testing. He has been part of the BMS senior leadership team that has achieved 14 NDA’s over the last 10 years.